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A B S T R A C T
Parkinson's disease (PD) is caused by human physiological function and is ranked as the second most common
neurodegenerative disorder. One of the prominent therapies currently available for PD is the use of dopamine
agonists which mimic the natural action of dopamine in the brain and stimulate dopamine receptors directly.
Currently, available pharmaceutical drugs provide only temporary relief of the disease. Phytocompounds have
been identiﬁed as promising target of research in the quest for new pharmaceutical compounds as they can
produce secondary metabolites with novel chemical structure. In this review the drug development of Parkinson
disease has been analyzed using computational tools.
1. Introduction
Modern life has become increasingly stressful with every passing
day. Lack of physical movement and mental relaxations lead to all the
stress related disorders. Tension and restlessness aﬀect both the body
and mind, especially central nervous system, which acts as the
midpoint of regulating system [1]. Neurodegeneration is a process
which involves neuropathological condition and brain aging. The form
of cerebrum pathology is cerebrovascular illnesses includes stroke,
vascular demantia, etc. Neurodegenerative disease causes death in
large numbers throughout the world. According to recent statistics, the
total death rate is 8% during the 21st century [2]. The major health
problems are cognitive dysfunction, neuropsychiatric and neurodegen-
erative disorders e.g. schizophrenia depression [3].
The most second common neurodegenerative disorder is Parkinson
disease, which completely aﬀects standard of life, causes dependency
and premature mortality of the diseased person [4]. Bradykinesia,
rigidity, postural instability or facial dyskinesia, muscular stiﬀness and
tremor characterize pathological distinctive sign are prominent symp-
toms of Parkinson's disease [5].
Besides these, sleep disorders, cognitive impairment, depression,
mood ﬂuctuations, psychosis and dementia are considered as non-
motor complications [6]. Central nervous system can be defended by
neuroprotection against neuronal injury owing to the two, acute and
chronic neurodegenerative disorders. The report of Essa et al, [2]
shows that prevalence rate of Parkinson's disease is 0.5–1% among the
age group of 80 and above.
The current treatment strategies for neurodegeneration do not
reduce it in half [7]. Drug researchers are concentrating on ﬁnding
new therapies based on phytochemical constituents and food supple-
ment for the neuroprotective eﬀects in Parkinson's disease with the
help of computational chemistry [8]. Recently, available therapeutics
applied for the neuropsychiatric and neurodegenerative disorders give
a symptomatic relief, not a permanent relief [9]. Treatment strategies
for reducing the progression of Parkinson's disease are yet to be
invented and the present work is a step in this direction. The
computational chemistry has become an economic tool for drug
discovery and identiﬁcation of lead molecules. This when coupled with
natural products enables a medicinal chemist to explore the available
options more eﬃciently with minimum labor [10].
2. Cause of Parkinson's disease
Identifying one particular cause for the formation of Parkinson’s
disease would be a Herculean task. A lot of theories on factors leading to
its development exist. Gene mutations related to early onset of PD have
been discovered. A new mutation on LRRK2 gene relating to idiopathic
PD has been identiﬁed. A statistical report shows that 15–20% of
patients with Parkinson’s disease are close relatives of people having
Parkinsonism symptom. It has been shown that 12 family members of a
patient with PD runs 3–4 times higher risk of developing PD compared
to the ordinary people. According to a theory, it is possible to predict if
an individual will develop PD or not, by putting together the right factors
with a predisposition based on the family history [11].
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Neurons were damaged despite the fact that oxidation caused by
free radicals circulating in the brain. Free radicals are referred as
endogenous toxins by some of the researchers. Pesticides are environ-
mental toxins which cause degeneration of the dopamine producing
cells. It is a well known fact that the risk for PD is elevated by the
herbicide parquet. It seems that smoking minimizes the risk of
developing PD, even though the reason for this hasn’t been understood
well yet (Fig. 1). The patient aﬀected by PD in normal age, undergoes
accelerated death of brain cells as PD causes the dopamine-producing
cells to age and die faster than normal [12].
3. Pathological characteristics of Parkinson's disease
Pathologically, Parkinson's disease is characterized by symptoms
like bradykinesia, rigidity, postural instability or facial dyskinesia,
muscular stiﬀness and tremor [7]. Sleep disorders, cognitive impair-
ment, depression, mood ﬂuctuations, psychosis and dementia are
identiﬁed as the other associated complications involved [13]. The
etiology of the neuronal cell death is still unclear, but mitochondrial
dysfunction, oxidative stress and subsequent apoptotic cell death have
been considered as underlying mechanisms of dopaminergic cell death
[14]. Although the current therapeutics applied for this disorder brings
forth a symptomatic relief, treatment strategies for slowing down the
disease progression are yet to be developed.
4. Role of medicinal plants in Parkinson diseases
Recently, numerous ethnobotanical studies were reported this
medicinal plant based medication therapy is a better feel than synthetic
drug treatment. The importance and uses of medicinal plants were
collected from the previous research ﬁndings respectively Table 1 [15–
30]. On the other hand medicinal plants are in use to treat memory
impairment in healthy individuals and those in states of disease.
Herbal medicines (Ayurveda) have been reported to be neuroprotective
via positive feedback of the neuronal meshing [3]. Furthermore the
Asian nations like India and China utilized more than one twenty
medicinal plant drugs were dealt against the Central nervous system
issues. Particularly, Indian system of medication recorded such a
nature of herbal plants like Acorus calamus, Allium sativum,
Centella asiatica, Ginkgo biloba, Glycyrrhiza glabra, Terminalia
chebula, Withania somnifera and other few medicinal plants are had
the eﬃcient productive activity in neuropsychopharmacology.
Diﬀerent civilizations, since time immemorial, have developed
traditional practices of treating illness with medicinal plants some of
which may look strange and magical, while others may look rational
and sensible. But all of them are intended to remediate the hardships of
illness and suﬀering, aiming to improve the quality of life. Thousands
of plants, found all over the world with medicinal properties, contain
potential ingredients that have pharmacological eﬀects on the human
body [3]. Human brain being a very complex organ, all the drugs are
not approved for the treatment of brain related illnesses [12].
Levodopa, cycrimine, carbinoxamine and carbidopa are authorized
drugs approved by regulatory authorities to treat Parkinson [11].
Anciently, ayurveda is exterior alternative medication in Indian
subcontinent described by Parkinson disease [31]. Seed of Mucuna is
an existing medication therapy for PD [32]. Mucuna pruriens contain
the high amount of Levodopa, it given long-losting amelioration of
Parkinson disease [33,34]. Powdered seed demonstrated the clinical
trials in PD patients among fast onset of action with no associated
boost in dyskinesia [35].
Numerous classes of plant based natural medicine and manufac-
tured conventional synthetic neuroprotective agent have been ac-
counted. On the other hand, synthetically manufactured neuroprotec-
tive agents are accepted to have certain negative reactions were showed
the human beings, for example, dry mouth, tiredness, sluggishness,
drowsiness, tension or apprehension, trouble with balance, etc. Plant
based products contain drawn widespread consciousness from through
research and endeavors at the national and global levels in current
scenario [36]. There are some phytochemicals which show cognitive
function related biological activities but neither the observed eﬀects
nor the mechanisms of action have been well characterized.
Phytoconstituents are stimulating cell stress-reaction pathways out
coming in regulation of neuroprotective excellence. Few phytocom-
pounds were demonstrated in Fig. 2. Intensifying evidence has
established that the neuroprotective impacts of the neurotrophic
components are mostly mediated by hamper the cell injure damage/
apoptosis pathways [37].
In silico and in vitro models indicated that the phytoconstituents
were shown exert neuroprotective activities in Tables 2 and 3 [38–
58]. In addition, medicinal plants are having numerous phytochem-
icals with diﬀerent secondary metabolites nature like Poly phenols
(phenolic acids, anthocyanins, proanthocyanidins, ﬂavonols, tan-
nins), isoprenoids (sesqiterpenes, diterpenes, triterpenes, steroids,
saponins), alkaloids (indole alkaloids, lysergic acid diethylamide,
Fig. 1. Location of Parkinson disease aﬀected region of human body.
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tropane alkaloids, ergot group) and fatty acid are dynamic constitu-
ents are found in lot of herbal plants and administered the diﬀerent
kinds of enzymes and with that cell receptors [59]. Though there are
many medicinal plants in traditional use across civilizations for the
treatment of cognitive disorders, only a few have been studied
extensively to determine the pharmacological basis for their medicinal
eﬀects. Some of them have invoked special interest among researchers
in understanding their potential and utility in the treatment of
cognitive impairment [60].
5. Computer aided drug design
Computer aided diagnosis is an important and promising branch of
bioinformatics where a computer system, capable of mimicking human
reasoning, is used to provide accurate diagnoses. Electronic medical
record which is an integrated patient speciﬁc genomic data is used for
improving patient care. Despite all these advances, there is no cure
available for Parkinson’s disease, yet. This makes new therapeutic
strategies the need of the hour to give proper care and treatment
Parkinsonian patients. Neuroproteomics, with its ability to quantify
proteins, can render help to study the neuronal changes associated with
neurodegeneration. Application of this technology can lead to a
presymptomatic diagnosis of Parkinson’s disease and also to the
determination of the various risk factors and the identiﬁcation of
new therapeutic targets for pharmacological intervention [61].
5.1. Structure based drug design
Structure based drug design is a major part of drug discovery and it
is a collection of technologies involving molecular biology, computa-
tional chemistry and bioinformatics. At present computational ﬁgures
were draw and designing with the help of Schrodinger computational
suite respectively (Fig. 3). Structure of the chemical compound or drug
can be obtained using X-ray crystallography or NMR spectroscopy
while structure based drug design with the help of computational tools
can predict how the designed drug molecule binds and interacts with
the target protein. Design of chemical compounds and structure based
drug design complement each other. Structure based drug design
revolves around de novo synthesis of compounds that can ﬁt into the
active site of the target protein, complementing it in terms of geometry,
charge, energy and other binding parameters [62].
5.1.1. Homology modeling
Homology modeling is an important process for the creation of new
target from the FASTA sequences. In this case, there are predictive
tools for building with that comparative model target. This method to
ﬁnd out modeled target sequence identities, similarities and gaps are
ﬁnding with globally conserved other protein sequences. Homology
modeling is one of the phenomenon try out for the target evaluation in
computational tools. These tools will helpful for the drug identiﬁcation
and development process. Some of the software's were frequently used
for the purpose of homology modeling respectively MODELER [63]
and SWISS-MODEL [64].
5.1.2. Sitemap generation
Sitemap validation is vital role in the route of molecular docking.
The target molecule had some active sites with eﬀective residues. But
this molecule did not show the eﬃcient active site thus the study
ﬁnding that one. Site validation analysis was displaying ligand binding
location, amino acid residues and site score. The binding site is larger
volumes were taken as a grid generation. The whole protein molecules
validated the binding site through site map generation tools in lot of
computational tools especially Schrodinger suite [65].
5.1.3. Grid generation
Grid generation is very important to ﬁxing target site of proteinTa
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molecules. Complex of ligands are docked into target receptors in
order to ﬁnd docking parameters with the help of Grid- Based ligand
docking with computational tools. The active site was explained with a
10 A radius around the ligand existing in the crystal structure. From
the glide programme the default grid size was taken. For the evasion
hand potential function Glide docking parameters were setup and for
all the docking studies non-constraints were applied. The docking
study carried out the grid generation at the centroid of the target site.
The X: Y: Z coordination was generated with grid box. The target site
was explained with a 10 A° radius around the ligand exists in the
crystal structure. The ligand center was placed at various grid
positions of a 10 A° grid and then rotated it around three Euler
angles. Crude score values and geometrical ﬁlters weed out unlikely
binding modes at this stage. For the default hand potential function
Glide docking parameters are setup and for all the docking studies
non-constraints were applied.
5.1.4. Molecular docking
Molecular docking is often used to predict the putative geometry of
a protein ligand complex [66]. In virtual screening experiments dock-
ing is frequently used in conjunction with scoring functions for
predicting the binding aﬃnities of ligands [67]. The ultimate aim of a
good docking function is to diﬀerentiate between many kinds of true
and false solutions. Estimation of the optimum kinetic performance of
the enzymes and the maximal ligand binding are part of the docking
process. For the free energy of ligand binding, both the empirical and
theoretical bounds are to be considered. This review shows that the
empirical data also discloses a signiﬁcant trend of smaller contribu-
tions per atom as the relative molecular mass of the ligand is increased.
These observations are used in guiding the drug design strategies. This
representation is to prove handy when we don’t have much of
information available, regarding speciﬁc interactions between atoms
of the ligand and that target.
Fig. 2. Structure demonstrated some globally reported phytocompounds for Parkinson disease.
S. Vijayakumar et al. Informatics in Medicine Unlocked 5 (2016) 15–25
18
T
a
b
le
2
P
h
yt
oc
om
p
ou
n
d
s
an
d
it
s
ef
fe
ct
iv
e
in
te
ra
ct
io
n
s
w
it
h
th
at
P
ar
ki
n
so
n
's
ta
rg
et
s
am
in
o
ac
id
re
si
d
u
es
.
S
.
N
o
.
N
a
m
e
o
f
th
e
p
h
yt
o
co
m
p
o
u
n
d
s
M
o
le
cu
la
r
fo
rm
u
la
M
o
le
cu
la
r
w
e
ig
h
t
H
b
o
n
d
D
o
n
o
r
H
b
o
n
d
a
cc
e
p
to
r
T
a
rg
e
t
e
n
zy
m
e
A
m
in
o
a
ci
d
re
si
d
u
e
s
in
te
ra
ct
io
n
s
C
o
m
p
u
ta
ti
o
n
a
ll
y
a
n
a
ly
ze
d
li
te
ra
tu
re
s
1.
G
in
kg
ol
id
e
B
C
2
0
H
2
4
O
1
0
42
4.
39
85
6
g/
m
ol
3
10
D
op
am
in
e
D
2
re
ce
p
to
r
–
[3
8]
2.
C
u
rc
u
m
in
C
2
1
H
1
8
N
O
4
+
34
8.
37
1
g/
m
ol
2
4
C
at
ec
h
ol
-O
-m
et
h
yl
tr
an
sf
er
as
e
V
A
L
95
,
A
L
A
91
,
an
d
G
L
U
83
[3
9]
3.
E
to
rp
h
in
e
C
2
5
H
3
3
N
O
4
41
1.
53
38
2
g/
m
ol
2
5
A
lp
h
a-
Sy
n
u
cl
ei
n
G
L
Y
86
[4
0]
4.
N
ar
in
ge
n
in
C
1
5
H
1
2
O
5
27
2.
25
2
g/
m
ol
3
5
A
lp
h
a-
Sy
n
u
cl
ei
n
SE
R
87
[4
0]
A
L
A
91
SE
R
87
5.
G
la
br
id
in
C
2
0
H
2
0
O
4
32
4.
37
g/
m
ol
2
4
d
op
am
in
e
re
ce
p
to
r
D
3
Se
r1
92
,
P
h
e3
45
,
A
sp
11
0,
Il
e1
83
[4
1]
6.
Q
u
er
ce
ti
n
C
1
5
H
1
0
O
7
30
2.
23
5
g/
m
ol
5
7
M
on
oa
m
in
e
ox
id
as
e
A
IL
E
,5
1
[4
2]
A
R
G
,5
2
T
H
R
,4
06
C
Y
S,
40
7
T
Y
R
,
43
5
T
H
R
,4
36
G
L
U
,4
45
M
E
T
,4
48
A
L
A
7.
C
ya
n
id
in
C
1
5
H
1
1
O
6
28
7.
24
4
g/
m
ol
5
5
C
at
ec
h
ol
am
in
e
O
-M
et
h
yl
T
ra
n
sf
er
as
e
G
L
U
90
,
A
SP
14
1,
L
Y
S1
44
,
A
SN
17
0
[4
3]
8.
B
ai
ca
le
in
C
1
5
H
1
0
O
5
27
0.
23
6
g/
m
ol
3
5
D
op
am
in
e
re
ce
p
to
r
D
3
A
SP
14
1,
L
Y
S1
44
,
A
SN
17
0,
G
L
U
19
9
[4
4]
9.
R
es
ve
ra
tr
ol
C
1
4
H
1
2
O
3
22
8.
24
3
g/
m
ol
3
3
A
lp
h
a-
sy
n
u
cl
ei
n
SE
R
87
[4
0]
10
.
H
es
p
er
id
in
C
2
8
H
3
4
O
1
5
61
0.
56
g/
m
ol
8
15
Su
lf
on
yl
u
re
a
re
ce
p
to
r-
1
G
L
Y
83
1,
L
E
U
82
9,
A
SN
82
8,
G
L
N
83
3,
[4
5]
11
.
M
ag
n
ol
ol
C
1
8
H
1
8
O
2
26
6.
33
4
g/
m
ol
2
2
D
op
am
in
e
re
ce
p
to
r
D
3
A
sp
11
0,
Il
e1
83
,
Se
r1
92
,
P
h
e3
46
,
T
h
r3
69
[4
4]
12
.
K
ae
m
p
fe
ro
l
C
2
1
H
2
0
O
1
44
8.
37
69
g/
m
ol
4
6
M
on
oa
m
in
e
ox
id
as
e
A
A
L
A
68
[4
6]
G
L
N
44
3
G
L
N
66
G
L
N
44
3
M
E
T
44
5
T
Y
R
69
A
SN
18
1
13
.
N
eo
an
d
ro
gr
ap
h
ol
id
e
C
2
6
H
4
0
O
8
48
0.
59
1
g/
m
ol
1
7
M
on
oa
m
in
e
ox
id
as
e
B
T
rp
13
5A
,
G
lu
14
1A
,
T
h
r
40
8
A
,
G
ln
40
9
A
,
A
rg
41
2
A
,
L
ys
14
9
B
,
[4
7]
14
C
af
fe
in
C
8
H
1
0
N
4
O
2
19
4.
19
g/
m
ol
–
3
A
d
en
os
in
e
A
2A
re
ce
p
to
r
H
is
-2
78
[4
8]
15
R
os
m
ar
ic
ac
id
C
7
H
4
C
lN
O
4
20
1.
56
4
g/
m
ol
5
4
C
as
p
as
e-
3
A
R
G
17
9,
SE
R
23
6,
G
lN
28
3,
A
R
G
34
1,
P
H
E
38
1
[4
5]
16
.
A
m
en
to
fl
av
on
e
C
3
0
H
1
8
O
1
0
53
8.
45
7
g/
m
ol
6
10
C
at
ec
h
ol
am
in
e
O
-M
et
h
yl
L
Y
S1
44
,A
SN
17
0,
P
R
O
17
4,
G
L
U
19
9,
M
G
[4
0]
T
ra
n
sf
er
as
e
S. Vijayakumar et al. Informatics in Medicine Unlocked 5 (2016) 15–25
19
T
a
b
le
3
In
vi
tr
o
st
u
d
ie
s
d
em
on
st
ra
te
d
th
at
th
e
p
h
yt
oc
om
p
ou
n
d
s
w
er
e
in
vo
lv
in
g
va
ri
ou
s
en
zy
m
es
ac
ti
vi
ti
es
.
S
.
N
o
.
N
a
m
e
o
f
th
e
P
h
yt
o
co
m
p
o
u
n
d
s
N
a
tu
re
o
f
P
h
yt
o
co
m
p
o
u
n
d
In
v
it
ro
m
o
d
e
l
M
e
ch
a
n
is
m
R
e
fe
re
n
ce
s
1.
6-
Sh
og
ao
l
P
h
en
ol
P
C
12
ce
ll
s
ex
p
os
ed
to
6-
O
H
D
A
R
at
m
es
en
ce
p
h
al
ic
ce
ll
s
ex
p
os
ed
to
M
P
T
P
In
cr
ea
se
th
e
C
el
l
vi
ab
il
it
y;
[4
9]
R
ed
u
ce
th
e
N
O
an
d
T
N
F
-Α
ac
ti
vi
ty
2.
H
es
p
er
id
in
F
la
vo
n
oi
d
SK
-N
-S
H
n
eu
ro
bl
as
to
m
a
ex
p
os
ed
to
ro
te
n
on
e
In
cr
ea
se
C
el
l
vi
ab
il
it
y;
In
cr
ea
se
le
ve
l
of
G
SH
(G
lu
ta
th
io
n
e)
;
In
cr
ea
se
th
e
an
ti
ox
id
an
t
p
er
fo
rm
an
ce
:
R
ed
u
ce
th
e
R
ea
ct
iv
e
O
xi
d
at
io
n
Sp
ec
ie
s;
In
cr
ea
se
th
e
L
P
O
;
In
cr
ea
se
th
e
M
M
P
;
In
cr
ea
se
th
e
an
ti
ap
op
to
ti
c
p
er
fo
rm
an
ce
:p
ro
te
ct
io
n
of
M
M
P
;R
ed
u
ce
th
e
cy
to
ch
ro
m
e
c
re
le
as
e;
In
cr
ea
se
th
e
ca
sp
as
e-
3
an
d
-9
;
In
cr
ea
se
th
e
B
ax
;
In
cr
ea
se
th
e
B
cl
-2
[5
0]
3.
R
os
m
ar
in
ic
ac
id
C
in
n
am
at
e
M
E
S2
3.
5
ce
ll
s
ex
p
os
ed
to
M
P
T
P
In
cr
ea
se
th
e
C
el
l
vi
ab
il
it
y;
R
ed
u
ce
th
e
ap
op
to
si
s;
re
st
or
at
io
n
of
co
m
p
le
x
I
ac
ti
vi
ty
of
th
e
m
it
oc
h
on
d
ri
al
re
sp
ir
at
or
y
ch
ai
n
;
p
ro
te
ct
io
n
of
M
M
P
;
R
ed
u
ce
th
e
R
O
S;
In
cr
ea
se
th
e
D
A
;
In
cr
ea
se
th
e
B
cl
-2
/B
ax
;
In
cr
ea
se
th
e
ca
sp
as
e-
3
ac
ti
vi
ty
[5
1]
4.
R
es
ve
ra
tr
ol
St
il
be
n
e
SH
-S
Y
5Y
n
eu
ro
bl
as
to
m
a
ce
ll
s
R
ed
u
ce
th
e
L
D
H
an
d
th
e
en
zy
m
e
of
ca
sp
as
e-
3
ac
ti
vi
ty
[5
2]
ex
p
os
ed
to
6-
O
H
D
A
5.
A
m
bu
ro
si
d
e
A
P
h
en
ol
R
at
m
es
en
ce
p
h
al
ic
ce
ll
s
ex
p
os
ed
to
6-
O
H
D
A
In
cr
ea
se
th
e
C
el
l
vi
ab
il
it
y;
R
ed
u
ce
th
e
n
it
ri
te
an
d
L
P
O
[5
3]
6.
O
le
u
ro
p
ei
n
T
er
p
en
e
P
C
12
ce
ll
s
ex
p
os
ed
to
6-
O
H
D
A
In
cr
ea
se
th
e
C
el
l
vi
ab
il
it
y;
R
ed
u
ce
th
e
cl
ea
ve
d
ca
sp
as
e-
3
an
d
R
O
S;
R
ed
u
ce
th
e
B
ax
/B
cl
-2
an
d
D
N
A
fr
ag
m
en
ta
ti
on
[5
4]
7.
P
ae
on
if
lo
ri
n
P
C
12
ce
ll
s
ex
p
os
ed
to
M
P
T
P
In
cr
ea
se
th
e
C
el
l
vi
ab
il
it
y
an
d
L
C
3-
II
/L
C
3-
I
ra
ti
o;
R
ed
u
ce
th
e
α
-s
yn
ac
cu
m
u
la
ti
on
an
d
le
ve
l;
m
od
u
la
ti
on
of
A
SI
C
ac
ti
vi
ty
an
d
p
ro
te
in
ex
p
re
ss
io
n
[5
5]
8.
C
ar
n
os
ic
ac
id
SH
-S
Y
5Y
n
eu
ro
bl
as
to
m
a
ce
ll
s
ex
p
os
ed
to
6-
O
H
D
A
In
cr
ea
se
th
e
C
el
l
vi
ab
il
it
y
an
d
cl
ea
ve
d
ca
sp
as
e-
3
an
d
P
A
R
P
;
In
cr
ea
se
th
e
R
O
S,
n
u
cl
ea
r
d
am
ag
e,
JN
K
an
d
p
38
p
h
os
p
h
or
yl
at
io
n
,
G
SH
,
N
rf
2
an
d
A
R
E
-l
u
ci
fe
ra
se
re
p
or
te
r
ac
ti
vi
ty
[5
6]
9.
P
ed
ic
u
la
ri
os
id
e
A
R
at
m
es
en
ce
p
h
al
ic
ce
ll
s
ex
p
os
ed
to
M
P
T
P
In
cr
ea
se
th
e
T
H
-p
os
it
iv
e
ce
ll
s
an
d
ce
ll
vi
ab
il
it
y;
R
ed
u
ce
th
e
ca
sp
as
e-
3
ac
ti
vi
ty
an
d
cl
ea
ve
d
P
A
R
P
[5
7]
10
.
d
l-
3-
n
-
B
u
ty
lp
h
th
al
id
e
B
en
zo
fu
ra
n
P
C
12
ce
ll
s
ex
p
os
ed
to
M
P
T
P
In
cr
ea
se
th
e
C
el
lv
ia
bi
li
ty
an
d
G
SH
;
R
ed
u
ce
th
e
N
O
an
d
H
O
2
2-
in
d
u
ce
d
to
xi
ci
ty
;
In
cr
ea
se
th
e
M
M
P
;
R
ed
u
ce
th
e
α
-s
yn
ac
cu
m
u
la
ti
on
[5
8]
S. Vijayakumar et al. Informatics in Medicine Unlocked 5 (2016) 15–25
20
5.2. Ligand based computer aided drug design
The new ligand identiﬁed in order of functional groups, nitrogen
and other contacts of molecules are interacting with the target residues.
The ligand based computer aided drug design showed the eﬃcient
molecule binding aﬃnities, physicochemical properties, glide energy,
score etc. In this step is highly victorious process than the structured
based design [68]. The process relies on the physiological properties of
small molecules. Furthermore, ligand based drug design is a more
phenomenon try out for ﬁnding eﬃcient inhibitor (ligand) against the
target [69].
5.2.1. Absorption, description, metabolism and excretion analysis
In the beginning stage of drug discovery physico-chemical indica-
tors were used in order to ﬁnd the vital properties aﬀecting the
biological functions (Table 4) [70–78]. There are some important
measured physico chemical properties such as permeability, solubility,
lipophilicity, integrity and stability. But the concept of ADME has been
expanded by toxicity [65]. At the initial stage of drug discovery not only
the several end points related to potential hazardous eﬀects that made
an impact on drug eﬃciency and drug toxicity were not estimated but
also carcinogenicialcy and mutagencity of a drug [79,80]. Right from
the beginning of drug discovery in silico method has been used to give
an accurate prediction of pharmacokinetic properties for instant
ADMET [81].
5.2.2. Quantitative structure activity relationship (QSAR)
It is the process by which chemical structure is quantitatively
correlated with a well deﬁned process for instance, a biological activity
or a chemical reactivity. This study forms the center stage when a
protein is the target. And a suitable molecule is needed to control the
activity of its target. Basic principle of this study is based on the
structure dependence of chemical activity. QSAR based in silico
analysis is regarded as an exercise to screen or ﬁlter ligand molecules.
Particularly these ligand molecules are very diverse [82]. Explain their
structure as well as chemical nature in order to screen them properly
and perfectly. This leads to the issue of ﬁnding descriptors of molecular
properties of ligands and drugs. These pyhsico chemical descriptors
include parameters accountable for hydrophobicity, topology, electro-
nic properties and steric eﬀects. They are resolved empirically or by
computational methods, as being done recently. This study shows that
QSAR is very useful for predicting drug like properties of the ligand
molecules performed with UCHL – 1 [83]. Good structural descriptors
are representatives of molecular features. Now, they are responsible for
the relevant activity. The use of QSAR is to identify chemical structures
which could have good inhibitory eﬀects on speciﬁc targets and have
low toxicity (non – speciﬁc activity).
According to Lipinski's rule of ﬁve, Log p is an important measure
used in identifying 'drug likeness' [84]. According to this rule, an orally
active drug is not to violate more than one of the following criteria:
1. Not more than 5 hydrogen bond donors.
2. Not more than 10 hydrogen bond acceptors.
3. A molecular weight under 500 Daltons.
4. Anoctanol – water coeﬃcient Log. p of less than 5.
5.2.3. Log p
Log p is a very important hydrophobic parameter. It is always used
in QSAR because it gives a measure of bioavailability of compounds
and resolves, in part, the amount of the compounds that gets to the
target site. Log P is used as a measure of lipophilicity which is a key
determinant pharmacokinetic property. Its relation with the hydro-
phobicity of the compound underlines its usefulness. It plays a key role
in the modulation of many ADME processes like drug membrane
interactions, biotransformation, drug transport and receptor binding,
all of which are related to hydrophobicity. By then, contour maps of
hydrophobic and hydrophilic ﬁelds were delivered. The hydrophilic
maps were additionally divided donor, acceptor and metal-binding area
Fig. 3. Computer aided drug design involved two kinds of process namely (i). Structure based drug design (ii). Ligand based drug design. This ﬁgure represented only the structure drug
based design process like homology modeling, target site validation, grid generation and molecular docking.
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Table 4
Physico-chemical properties reported phytocompounds compounds.
S. No. Phytocompounds Name and Structure with
references
Donor HB Acceptor HB N and O Ring
atom
Human Oral
Absorption
IP Value References
1 Mescaline 1 4 4 6 3 8.693 [70]
2 Eriodictyol 4 6 6 16 2 8.976 [71]
3 Gingerol 2 4 4 6 3 8.696 [72]
4 Apigenin 3 5 3.75 5 16 3 [73]
5 Kaempferol 3 4.5 6 16 3 [74]
6 Wogonin 2 5 3.75 5 16 3 [75]
7 Curcumin 2 6 7 6 12 2 [76]
8 Dronabinol 1 2 1.5 2 14 1 [77]
9 Tocotrienol 1 2 1.5 2 10 1 [78]
(continued on next page)
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(Fig. 4). According to the Rule of ﬁve, if the Log P of a compound is less
than ﬁve, it is likely to be strongly absorbed.
6. Conclusion
The conventional medicines and treatment, available today, have
proven ineﬀective in curing the multifunctional pathological mechan-
isms of Parkinson’s disease. Use of bioactive compounds of medicinal
plants, on the other hand, has shown to possess the potential to modify
or slow down the progress of Parkinson disease. Identiﬁcation of new
bioactive compounds becomes the need of the hour to develop new and
eﬀective drugs. Pharmacoinformatics approach has to be followed in
the modern drug design to understand the drug-receptor interaction.
On the basis of this review, it is concluded that modern computational
methods can strongly support and facilitate the design of novel,
eﬀective and more potent inhibitors for the Parkinson disease with a
better understanding of the drug and receptor interactions. The
computational tools made the time save, avoid risk, low cost and easy
to detect the eﬃcient molecules with that selected target.
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